Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-24

Study Completion Date

2020-04-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Norgestrel 75 mcg is a progestin-only pill (POP), which is a kind of oral birth control pill.

To be effective in preventing pregnancy, this kind of birth control pill is supposed to be taken every day at the same time, without delaying the intake for more than 3 hours.

This study aims to find out if taking the pill 6 hours late or not taking it for one day will affect the way it works.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Oral Contraception Under Simulated OTC Conditions

NCT03559010

Contraception

TERMINATED PHASE3

Metabolism of 0.35mg Norethindrone vs 5mg Norethindrone Acetate

NCT05294341

Contraception

COMPLETED PHASE4

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

NCT03662516

Healthy Females

COMPLETED PHASE1

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

NCT04112095

Contraception

COMPLETED PHASE3

Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers

NCT01246791

Healthy

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an exploratory, prospective, multi-center, randomized, cross-over study to assess the effect of norgestrel 75 mcg on cervical mucus and ovarian activity during reported perfect daily use, after a delayed intake of 6 hours and after a missed pill.

After a screening period up to one month, depending on the menstrual cycle of the subject, the subjects will take norgestrel 75 mcg for three 28-day treatment periods, every day at the same time except for one day in the middle of treatment period 2 and treatment period 3 where they will either take it 6 hours late or not take it.

In week 5 (1st visit of treatment period 2), they will be randomized to 2 sequences, either 6 hours delayed intake in treatment period 2 and missed pill in treatment period 3 or the opposite.

After the end of treatment period 3, a follow-up up to 12 days may be required to follow ovarian activities.

Subjects will have visits twice a week and sometimes more often to assess the effects of the pill on:

* cervical mucus properties by a cervical mucus sampling
* ovarian activity by a vaginal ultrasound (TVUS)
* reproductive hormones levels by a blood sample (Progesterone (P4), Estradiol (E2), Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH))
* plasma drug level by a blood sample

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Contraception

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: Delayed then Missed Pill

Treatment period 2, Day 42 +/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: missed pill of Norgestrel 75 mcg

Group Type OTHER

Norgestrel 0.075 mg

Intervention Type DRUG

Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3

Arm B: Missed then Delayed Pill

Treatment period 2, Day 42 +/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg

Group Type OTHER

Norgestrel 0.075 mg

Intervention Type DRUG

Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Norgestrel 0.075 mg

Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Norgestrel 75 mcg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women in good overall health with no chronic medical conditions that result in periodic exacerbations that require significant medical care
* Women between 18 and 35 years inclusive at the screening visit
* BMI\< 32 kg/m²
* Regular menstrual cycles between 21 and 35 days when not using hormonal contraception.

* Subjects postpartum or post-abortal must have one normal menstrual cycle (2 menses) prior to enrollment.
* Subjects previously using Intra-Uterine Device (IUD) or taking hormonal contraception (or any other hormonal treatment, except an injectable treatment) need to have at least one menstrual cycle (2 menses) without the treatment before screening.
* Subject previously using an injectable (DMPA), must have had their last injection at least 9 months before screening.
* Women not at risk of pregnancy: not sexually active, or willing to protect all acts of intercourse with condoms, or have a sterile partner or have undergone previous tubal ligation (including validated Essure), or be in a same sex relationship.
* Women able to give informed consent form to participate in the study and in the opinion of the investigator able to follow all study requirements, use the study medication and record the requested information appropriately
* Intact uterus and both ovaries
* At least one progesterone concentration \> 3 ng/mL (\>10 nmol/L) during the luteal phase of the screening period

Exclusion Criteria

* Pregnant as confirmed by positive high-sensitivity urine pregnancy test at enrollment visit
* Trying to conceive or desire to conceive in the next 3 months
* Currently breastfeeding, or within the last 2 months
* Known Polycystic Ovarian Syndrome (PCOS)
* Cancer (or past history of any carcinoma or sarcoma)
* Known abnormal thyroid status, if in clinical judgment of the investigator it cannot be controlled during the study
* Known hypersensitivity to the ingredients of the test active substances or its excipients
* Current acute liver disease and/or benign liver tumors
* Have vaginal or cervical infection including clinical evidence of bacterial vaginosis
* Evidence of abnormal cervical lesion
* History of excisional or ablative treatment procedure on cervix (ie. Loop Electrosurgical Excision Procedure (LEEP), Cryotherapy, Cold Knife Cone)
* Undiagnosed abnormal uterine bleeding
* Prior malabsorptive-type bariatric surgery
* Known or suspected alcoholism or illicit drug abuse
* Use of any hormonal contraception or IUD other than the study medication during the study (including ulipristal acetate for emergency contraception in the past 5 days)
* Use of any medications that can interfere with the metabolism of progestin-based contraceptives (e.g CYP3A4 enzymes inducers or inhibitors, etc)
* Unstable diabetes mellitus
* Current participation in any other trial of an investigational medicine or participation in the past two months (or within 5 elimination half-lives for chemical entities or 2 elimination half-lives for antibodies, whichever is the longer) before screening
* Abnormalities in laboratory results or TVUS performed at screening visit recognized as clinically significant by the investigator
* Conditions not suitable for frequent TVUS examinations, (e.g. virgo intacta)
* In custody or submitted to an institution due to a judicial order
* Relative or household member of the investigator's or sponsor's staff

Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes